Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2016年 / 58卷 / 1485期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：2 / 4
页数：3
相关论文
共 50 条
  • [31] Upfront triple combination therapy with ambrisentan, tadalafil and subcutaneous treprostinil in incident patients with severe pulmonary arterial hypertension
    D'Alto, M.
    Romeo, E.
    Argiento, P.
    Badagliacca, R.
    Papa, S.
    Farro, A.
    Sarubbi, B.
    Russo, M. G.
    Vizza, C. D.
    Golino, P.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3037 - 3037
  • [32] AMBRISENTAN AND ITS ROLE IN THE MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION
    Maclntyre, Lain M.
    Dhaun, Neeraj
    Goddard, Jane
    Webb, David J.
    DRUGS OF TODAY, 2008, 44 (12) : 875 - 885
  • [33] Ambrisentan: a review of its use in pulmonary arterial hypertension
    Rivera-Lebron, Belinda N.
    Risbano, Michael G.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2017, 11 (06) : 233 - 244
  • [34] Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience
    Issapour, Azadeh
    Frank, Benjamin
    Crook, Sarah
    Hite, Michelle D.
    Dorn, Michelle L.
    Rosenzweig, Erika B.
    Ivy, D. Dunbar
    Krishnan, Usha S.
    PEDIATRIC PULMONOLOGY, 2022, 57 (03) : 724 - 733
  • [35] Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
    Elshaboury, Soha M.
    Anderson, Joe R.
    PATIENT PREFERENCE AND ADHERENCE, 2013, 7 : 401 - 409
  • [36] Ambrisentan: a guide to its use in pulmonary arterial hypertension
    Drugs & Therapy Perspectives, 2009, 25 (7) : 1 - 5
  • [37] Safety and Efficacy of Ambrisentan in the Treatment of Pulmonary Arterial Hypertension
    Valerio, Christopher J.
    Kabunga, Peter
    Coghlan, John G.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 541 - 556
  • [38] Correction to: Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU
    Katherine A. Lyseng-Williamson
    Jürgen Behr
    Drugs & Therapy Perspectives, 2018, 34 (10) : 496 - 496
  • [39] Correction to: Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU
    Katherine A. Lyseng-Williamson
    Jürgen Behr
    Drugs & Therapy Perspectives, 2019, 35 : 47 - 47
  • [40] Oral Tadalafil in Children with Pulmonary Arterial Hypertension
    Shiva, A.
    Shiran, M.
    Rafati, M.
    Zamani, H.
    Babazadeh, K.
    Saeedi, M.
    Ala, S.
    DRUG RESEARCH, 2016, 66 (01) : 7 - 10
12345